SRPK1 reduced expression—induced either through gene knockdown or the SRPK1 inhibitor SPHINX—suppressed angiogenesis thus tumor growth in vivo through a switch in VEGF alternative splicing. This evidence concerns the gene VEGFA and neoplasm.